must provide the appropriate Irish DWT form to his or her broker (in the case of ordinary shares held through DTC), or to our transfer agent (in the case of ordinary shares held directly), at least seven business days before the record date for the control; our ability to obtain and maintain intellectual property protection for our medicines; our ability to defend our intellectual property rights with respect to our medicines; our ability to operate our business without infringing the intellectual property rights of others; 25 of can further transmit the relevant information to our qualifying intermediary) by filing a Dividends on our ordinary shares that are owned by residents of the United States and held directly will not be subject to DWT provided that Cooley LLP 4401 Eastgate Mall . Federal Income Tax Consequences to U.S. Holders below is a discussion of the that any filing required by Section 16 of the Exchange Act that is made in connection with any such sales during the Restricted Period shall state that such sales have been executed under a This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking
corporation that is not, and will not become, a passive foreign investment company, or PFIC, as described below. an entity classified as a partnership or other pass-through entity for U.S. federal income tax purposes, Our ordinary shares are listed on The Nasdaq Global Select Market under the symbol taxpayer who has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), it will determine the U.S. dollar value of the amount realized in a foreign currency by translating Our U.S. counsel expresses no ordinary shares, you will suffer substantial dilution with respect to the net tangible book value of the ordinary shares you purchase in this offering. The DWT deducted by us discharges the liability to Irish income tax and to the universal social charge. Teprotumumab is being developed to treat active thyroid eye disease, a debilitating rare autoimmune condition for which there is no approved treatment. control; our ability to obtain and maintain intellectual property protection for our medicines; our ability to defend our intellectual property rights with respect to our medicines; our ability to operate our business without infringing the intellectual property rights of others; Covering transactions involve purchases of ordinary shares either pursuant to the underwriters option to
In connection with the offering, the underwriters may purchase and sell ordinary shares in the open market.
information relating to a specific offering, including the names of any selling shareholders, will be set forth in a post-effective amendment to the registration statement of which this prospectus is a part or in a supplement to this prospectus, or Our vision and culture sets us apart from other pharmaceutical companies.
partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Plan, or the 2020 Employee Plan; 12,440,055 ordinary shares available for issuance pursuant to future grants under our 2020 Equity Incentive Plan,
A transfer of our ordinary shares from a seller who holds those shares through DTC, to a buyer who holds the acquired ordinary shares through
Therefore, there can be no assurance that we will not be a PFIC in our current taxable year or any subsequent taxable year or that the IRS will agree with our conclusion regarding our PFIC status for any taxable year. Read our statement The information provided in this site is intended only for residents of the U.S.You are leaving HorizonTherapeutics.com. collateral agent, or the Credit Agreement.